The releasing of functional siRNA from our RNA nanoparticles was documented by animal trials in multiple publications showing the inhibition of tumors in non-small-cell lung (NSCLC),81 triple negative breast (TNBC),30 and prostate30 cancer models when Survivin siRNA was fused onto RNA nanoparticles and delivered to tumors (Figure 5). Here, BIRC5 is linked to cancer.